Intravitreal Bevacizumab Injection in Diabetic Papillopathy
Journal of the Korean Ophthalmological Society
;
: 1298-1302, 2013.
Article
in Korean
| WPRIM
| ID: wpr-197743
ABSTRACT
PURPOSE:
To report a case where intravitreal bevacizumab injection was an effective treatment for diabetic papillopathy in a type 2 diabetic patient. CASESUMMARY:
A 47-year-old male with a 10-year history of diabetes mellitus type 2 presented to our clinic for evaluation of diabetic retinopathy. There were no subjective symptoms including blurred vision or visual defect, and best corrected visual acuity (BCVA) was 20/20 in the right eye and 20/30 in the left eye. Fundus examination showed hyperemic optic disc swelling with telangiectatic new vessels, and fluorescein angiography leakage from the optic disc with neovascularization. The patient underwent fractionated panretinal photocoagulation. Ten days later, he complained of painless blurred vision with significant optic nerve head swelling and BCVA was 20/80 in the left eye. Intravitreal bevacizumab injection was administered, optic disc swelling was significantly decreased and BCVA improved to 20/30 after two months.CONCLUSIONS:
Diabetic papillopathy with severe decreased visual acuity can be treated with intravitreal bevacizumab injection.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Optic Disk
/
Vision, Ocular
/
Fluorescein Angiography
/
Visual Acuity
/
Diabetes Mellitus
/
Diabetic Retinopathy
/
Eye
/
Antibodies, Monoclonal, Humanized
/
Bevacizumab
/
Light Coagulation
Limits:
Humans
/
Male
Language:
Korean
Journal:
Journal of the Korean Ophthalmological Society
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS